VVOS

+ Watchlist + Portfolio

Vivos Therapeutics, Inc.

Regulated industry Physical productsTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $0.15
52-Week Range: $0.13 – $3.42
Market Cap: $5.10M
P/E (TTM): —
EPS (TTM): -1.88
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: —
PEG Ratio: —
Return on Equity: -8585.26%
Return on Assets: -56.19%
Gross Margin: 61.90%
Operating Margin: -93.64%
Profit Margin: -121.79%
Current Ratio: 0.21
Debt/Equity: —
Total Debt: $12.51M
Free Cash Flow: $-8.53M
Revenue Growth: 34.90%
Earnings Growth: —
Enterprise Value: $14.72M

VVOS Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$16.02M	$13.80M	$15.03M	$17.44M
Cost of Revenue	$6.00M	$5.53M	$6.01M	$6.90M
Gross Profit	$10.02M	$8.27M	$9.02M	$10.54M
Selling, General & Admin	$34.38M	$24.95M	$19.61M	$29.13M
Operating Expenses	$35.05M	$25.57M	$20.19M	$30.44M
Operating Income	-$25.03M	-$17.30M	-$11.17M	-$19.89M
EBITDA	-$24.36M	-$16.68M	-$10.59M	-$18.59M
Pretax Income	-$23.84M	-$13.58M	-$11.14M	-$21.23M
Income Tax	$0.00	—	—	—
Net Income	-$23.84M	-$13.58M	-$11.14M	-$21.23M
Diluted EPS	-25.90	-11.14	-2.22	-2.07
Diluted Shares	920592	1.22M	5.02M	10.27M

VVOS Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$3.52M	$1.64M	$6.26M	$2.03M
Receivables	$457.00K	$202.00K	$430.00K	$1.58M
Current Assets	$5.42M	$2.46M	$7.47M	$4.38M
Total Assets	$13.72M	$10.73M	$15.28M	$25.15M
Current Liabilities	$6.81M	$7.29M	$4.98M	$18.08M
Long-Term Debt	—	—	—	$469.00K
Total Debt	$2.41M	$2.00M	$1.51M	$13.50M
Total Liabilities	$8.92M	$10.32M	$7.33M	$26.70M
Retained Earnings	-$79.47M	-$93.05M	-$104.19M	-$125.36M
Shareholders' Equity	$4.80M	$411.00K	$7.95M	-$1.49M
Working Capital	-$1.39M	-$4.83M	$2.50M	-$13.69M
Net Debt	—	—	—	$6.79M

VVOS Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$19.59M	-$11.95M	-$12.69M	-$15.26M
Capital Expenditure	-$924.00K	-$803.00K	-$568.00K	-$2.34M
Free Cash Flow	-$20.51M	-$12.75M	-$13.26M	-$17.60M
Depreciation & Amortisation	$669.00K	$621.00K	$581.00K	$1.31M
Stock-Based Compensation	$2.40M	$1.11M	$762.00K	$661.00K
Investing Cash Flow	-$924.00K	-$853.00K	-$568.00K	-$7.53M
Financing Cash Flow	$0.00	$10.92M	$17.88M	$18.56M
Share Repurchases	$0.00	—	—	—
Net Change in Cash	-$20.51M	-$1.88M	$4.62M	-$4.23M

VVOS Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$3.02M	$3.82M	$6.78M	$3.82M	$5.14M	$5.15M
Cost of Revenue	$1.51M	$1.71M	$2.85M	$836.00K	$2.08M	$2.20M
Gross Profit	$1.51M	$2.11M	$3.94M	$2.99M	$3.06M	$2.95M
Selling, General & Admin	$5.25M	$6.67M	$8.29M	$8.93M	$9.22M	$7.27M
Operating Expenses	$5.43M	$6.97M	$8.67M	$9.37M	$9.67M	$7.78M
Operating Income	-$3.92M	-$4.87M	-$4.73M	-$6.38M	-$6.62M	-$4.83M
EBITDA	-$3.74M	-$4.56M	-$4.35M	-$5.94M	-$6.16M	-$4.31M
Pretax Income	-$3.86M	-$5.01M	-$5.40M	-$6.95M	-$7.75M	-$5.52M
Net Income	-$3.86M	-$5.01M	-$5.40M	-$6.95M	-$7.68M	-$5.48M
Diluted EPS	-0.45	-0.55	-0.49	—	-0.52	-0.31
Diluted Shares	8.60M	9.09M	10.96M	—	14.63M	17.68M

VVOS Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$2.34M	$4.40M	$3.09M	$2.03M	$2.11M	$1.77M
Receivables	$718.00K	$1.63M	$2.13M	$1.58M	$1.77M	$1.44M
Current Assets	$3.61M	$6.73M	$5.79M	$4.38M	$4.82M	$4.21M
Total Assets	$11.28M	$26.03M	$25.64M	$25.15M	$25.04M	$24.14M
Current Liabilities	$4.70M	$6.43M	$7.44M	$18.08M	$17.94M	$20.39M
Long-Term Debt	—	$7.76M	$8.38M	$469.00K	$418.00K	$366.00K
Total Debt	$1.40M	$11.58M	$12.50M	$13.50M	$12.27M	$12.51M
Total Liabilities	$6.88M	$21.45M	$23.11M	$26.70M	$26.31M	$28.13M
Retained Earnings	-$108.05M	-$113.06M	-$118.46M	-$125.36M	-$133.04M	-$138.52M
Shareholders' Equity	$4.41M	$4.58M	$2.53M	-$1.49M	-$1.14M	-$3.81M
Working Capital	-$1.09M	$304.00K	-$1.65M	-$13.69M	-$13.12M	-$16.18M
Net Debt	—	$3.52M	$5.63M	$6.79M	$5.61M	$6.36M

VVOS Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$3.80M	-$3.49M	-$4.16M	-$3.81M	-$6.01M	-$3.15M
Capital Expenditure	-$122.00K	-$771.00K	—	-$1.53M	-$18.00K	-$416.00K
Free Cash Flow	-$3.92M	-$4.26M	-$4.08M	-$5.34M	-$6.03M	-$3.56M
Depreciation & Amortisation	$177.00K	$306.00K	$384.00K	$442.00K	$454.00K	$511.00K
Stock-Based Compensation	$317.00K	$242.00K	$55.00K	$47.00K	$151.00K	$50.00K
Investing Cash Flow	-$122.00K	-$5.91M	$83.00K	-$1.58M	-$18.00K	-$416.00K
Financing Cash Flow	$0.00	$11.46M	$2.76M	$4.33M	$6.11M	$3.23M
Net Change in Cash	-$3.92M	$2.06M	-$1.31M	-$1.06M	$81.00K	-$336.00K

Market Snapshot

About

Vivos Therapeutics is a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for obstructive sleep apnea and other sleep-disordered breathing conditions. The company offers non-invasive oral appliance therapies that aim to address underlying anatomical issues rather than just managing symptoms. Vivos utilizes proprietary protocols combining dental devices with patient monitoring and care coordination.